The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma

@article{Fumagalli2000ThePO,
  title={The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma},
  author={Luca A. M. Fumagalli and Massimo Zucchetti and Idria Parisi and Maria Grazia Vigan{\`o} and Bruno Zecca and Anna M Careddu and Maurizio D'Incalci and Adriano Lazzarin},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2000},
  volume={45},
  pages={495-501}
}
Purpose: To investigate the pharmacokinetics of liposomal daunorubicin (DaunoXome) administered alone or in combination with antiviral therapy including protease inhibitors (PI) to HIV-positive patients affected by Kaposi's sarcoma (KS). Patients and methods: A group of 18 patients with extensive or rapidly progressing AIDS-related KS received DaunoXome at a dose of 40 mg/m2 alone or in association with a triple combination therapy consisting of one PI plus two nucleoside reverse transcriptase… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 52 references

Evidence of immune reconstitution and HIV control following EPOCH chemotherapy (CT) for HIVrelated lymphomas (HIV-NHL)

  • RF Little, D Pearson, P Elwood, G Franchini, R Yarchoan, WH Wilson
  • Sixth Conference on Retroviruses and…
  • 1999
1 Excerpt

Similar Papers

Loading similar papers…